Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma
To evaluate of adjuvant therapy using oxaliplatin and gemcitabine (GEMOX regimen) versus capecitabine alone chemotherapy in patients who underwent curative surgery for intrahepatic cholangiocarcinoma (ICC) -- a randomized control study.
Cholangiocarcinoma
DRUG: oxaliplatin and gemcitabine|DRUG: capecitabine
Recurrence-free survival, from the date of surgery to the date of tumor recurrence up to 36 months after surgery
Overall survival, from the date of surgery to the date of death up to 36 months after surgery
Number of participants with adverse events and severe adverse events, All toxicities will be graded by CTCAE v4, from the date of first dosage to safety follow-up visit (30 days after the last dosage)
chemotherapy: GEMOX vs capecitabine alone; adjuvant settings; primary endpoint: recurrence-free survival (RFS); second endpoint: overall survival after surgery (OS).